Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Free Cash Flow (2024 - 2025)

Historic Free Cash Flow for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to -$19.1 million.

  • Prelude Therapeutics' Free Cash Flow rose 3013.27% to -$19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.3 million, marking a year-over-year change of. This contributed to the annual value of -$103.7 million for FY2024, which is 626.18% up from last year.
  • According to the latest figures from Q3 2025, Prelude Therapeutics' Free Cash Flow is -$19.1 million, which was up 3013.27% from -$26.1 million recorded in Q2 2025.
  • In the past 5 years, Prelude Therapeutics' Free Cash Flow registered a high of -$19.1 million during Q3 2025, and its lowest value of -$34.3 million during Q1 2025.